Need professional-grade analysis? Visit stockanalysis.com
$2.49B
21.49
3,610
1.93%
Dermapharm Holding SE (DMP) trades on XETRA (Frankfurt) in EUR. The company is classified in the Healthcare sector under the Drug Manufacturers - Specialty & Generic industry. The stock currently trades at EUR45.90, down 0.65% from the previous close.
Over the past year, DMP has traded between a low of EUR32.05 and a high of EUR47.25. The stock has gained 24.8% over this period. It is currently 43.2% above its 52-week low.
Dermapharm Holding SE has a market capitalization of $2.49B, with a price-to-earnings ratio of 21.49 and a dividend yield of 1.93%.
Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany, Italy, France, Austria, Switzerland, Spain, Portugal, the Netherlands, Croatia, Poland, Ukraine, the United States, and China. The company operates through three segments: Branded Pharmaceuticals; Other Healthcare Products; and Parallel Import Business. It offers branded generics, OTC products, non-prescription healthcare products, and herbal extracts and parallel-imported originator pharmaceuticals. The company also provides vitamins, minerals, food supplements, as well as products for dermatology, allergology, pain and inflammation treatment, cardiovascular support, gynecology, and urology. In addition, it offers cosmetics and medical devices. Further, the company imports originator pharmaceuticals under the axicorp brand. It sells its products under the Dekristol, Keltican, Tromcardin, Ketozolin, bite away, and Herpotherm brands. The company was founded in 1991 and is headquartered in Grünwald, Germany. Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-AG.
Side-by-side comparison against top Healthcare peers.